The purpose of this study is to test the effects of different doses of COR-003 on people with Cushing’s syndrome (CS) primarily by measuring the cortisol levels in urine and secondarily by measuring other health parameters such as blood pressure, weight, and liver function. This study is also being conducted to see if there is any harm caused when using COR-003.
This study is an open label study. That means both the health providers and the participants in the study are aware of the drug or treatment being given.
Adult Subjects (18 years or older) with elevated levels of cortisol due to endogenous CS.
Confirmed diagnosis of persistent or recurrent CS (with or without therapy) or newly diagnosed disease, if subjects are not candidates for surgery. CS will be defined according to the criteria in the guidelines for diagnosis of CS (Nieman 2008).
Women who are pregnant or lactating are not eligible for this study.
Individuals with other health conditions or diagnoses may not be eligible for this study.
These and other eligibility criteria are best reviewed with a doctor who is participating in the study. You can also get more detailed eligibility information about the study by clicking here to visit www.clinicaltrials.gov.
- The study will begin with a screening period to make sure subjects are eligible to participate in the study.
- After the screening period, subjects who are eligible for participation will each be given several different doses of COR-003, to be taken orally in tablet form.
- After an individualized dose has been selected, participants will take COR-003 for six months.
- Finally, participants will continue in the study for an additional six months at doses to be determined by the study doctor.
Throughout the study, participants will meet regularly with a study doctor and will take part in a variety of medical tests to make sure they are doing well and to see if COR-003 is working.
Participants in the study should be sure they have the time to participate. Participants will generally be followed for over a year:
The study is currently taking place in several places around the world (United States, Belgium, France, Israel, Netherlands, Spain, and Sweden).
Additional information on the study can be found at clinicaltrials.gov through this link.
Study sponsor: Cortendo AB
For more information, please contact: